GBD 209
Alternative Names: GBD-209Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Genor Biopharma
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Feb 2025 Pharmacodynamics data from a preclinical trial in Cancer released by Genor Biopharma (Genor Biopharma pipeline, February 2025)
- 12 Feb 2025 Preclinical trials in Cancer in China (Parenteral), prior to February 2025 (Genor Biopharma pipeline, February 2025)